Kumar and colleagues (1) conducted a costeffectiveness analysis (CEA) comparing lung cancer screening using risk-based criteria versus criteria based on NLST (National Lung Screening Trial) enrollment. They concluded, "Our analysis suggests that the gains from such risk-based eligibility likely would be small," implying approximate equivalence between these criteria. A critical limitation of their analysis is that their sample was limited to NLST participants and does not represent the general population of smokers. Of note, they did not evaluate smokers who met risk-based but not NLST criteria. Consider using NLST criteria and the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Model 2012 (PLCO M2012 ) 6-year risk for cancer of 1.5% or greater (2, LETTERS
3) to determine screening eligibility in smokers enrolled in the PLCO trial. Among 74 218 ever-smokers in the PLCO trial, 4929 would be screened following the PLCO M2012 but not NLST criteria and 157 (3.2%) cases of lung cancer would be diagnosed. A total of 7367 persons would be screened following NLST criteria but not the PLCO M2012 , and 59 (0.8%) cases of lung cancer would be detected. Selection based on the PLCO M2012 would detect 7.5% more cases of lung cancer and improve mortality, life-years gained, and quality-adjusted life-years, favoring risk-based selection. Previous analyses indicated that the PLCO M2012 would select 8.8% fewer persons but identify 12.4% more cases of lung cancer than NLST criteria (3). However, Kumar and colleagues did not examine the benefits of screening according to risk alone.
Another concern is public health policy. Race disparities exist in lung cancer risk and are accounted for in some risk prediction models. The NLST criteria ignore these disparities and underselect black persons for screening. Among PLCO participants who met NLST criteria but not the PLCO M2012 selection criteria, 141 black persons were screened; only 1 of these persons (0.7%) developed lung cancer. Among PLCO participants who did not meet NLST criteria but would have met the PLCO M2012 selection criteria, 618 black persons were screened; 21 of these persons (3.4%) developed lung cancer. Risk-based selection identifies more black persons at high risk for lung cancer and thus can reduce screening disparities. A similar argument can be made for disparities based on low socioeconomic status.
Kumar and colleagues' CEA is not supported by a probabilistic sensitivity analysis, which is required to account for combined parameter uncertainty and to minimize bias in public health decisions. Without using such a method, the analysis is limited to effects from the variables that the authors chose to describe. They deterministically combined 3 variables at once in an effort to account for combined parameter uncertainty but excluded many others-such as non-lung cancer outcomes-that most screened persons will experience. One of the authors (S.C.) and her associates (4) probabilistically evaluated risk-based selection using NLST and PanCan (PanCanadian Early Detection of Lung Cancer Study) criteria and showed that the greatest driver of screening costeffectiveness was non-lung cancer outcomes. Kumar and colleagues did not evaluate such outcomes. They also did not consider the budgetary effect of screening. If 81% of NLST participants were not screened (applying the PanCan selection criteria and a 6-year risk for lung cancer of 2% or greater), more than $20 million would be saved from baseline lowdose computed tomography examinations alone. Furthermore, these persons would be spared the risk for screening harms, such as false-positive nodules. Population-based microsimulation modeling has shown that resource use of computed tomography is a main driver of screening costs. Excluding low-risk persons would eliminate these costs (5) . The authors' CEA alone is not sufficient to support their conclusions against risk-based selection and does not provide adequate economic evidence to inform public health policy.
IN RESPONSE:
We acknowledge that our analysis focused on participants enrolled in NLST and thus is not directly germane to the question of cost-effectiveness of screening smokers excluded from this trial. Nevertheless, the fundamental point of our analysis-also shown by Dr. Cressman and colleagues (1) and applicable to high-risk, NLST-ineligible participants-is that those at the highest risk for lung cancer mortality have a high prevalence of clinical characteristics that adversely affect longevity, quality of life, and costs related to screening and management of both cancer-and noncancer-related findings. We agree with Dr. Cressman and colleagues that screening higher-risk patients substantially improves the efficiency of detecting lung cancer on a per-patient-screened basis, but the data that they present are not directly relevant to the question of whether it is substantially more efficient than a screen-all approach on the basis of quality-adjusted life-years per dollar.
Studies using lung cancer detected per patient screened or examining relatively short time horizons (2) are biased to overstate the value of stratification by lung cancer risk (or by lung cancer mortality risk), because the gradient between high-and low-risk patients attenuates (and may even reverse) over time. To our knowledge, our analysis is the first that fully accounts for the correlations between lung cancer mortality risk and other important dimensions (for example, life expectancy and cost) by modeling all the relevant transitions with the same level of granularity over a lifetime horizon. We also believe that it is the first to compare the cost-effectiveness across risk-defined groups.
Dr. Cressman and colleagues suggest that race and socioeconomic status be used in risk stratification and for screening selection. Race was included in our model; we caution that fully accounting for the effects of race (and socioeconomic variables) on all transitions, including long-term life expectancy, attenuates their value as screening selection factors. We also included noncancer contributions to mortality in our model, including any "unintended" beneficial effects that lowdose computed tomography screening may have on noncancer mortality. As we acknowledged in our article, noncancer morbidity was not accounted for; however, these effects would presumably attenuate the gradient between high-and low-risk patients more, because high-risk patients survive cancer with a higher burden of comorbid disease and a lower quality of life. We did not conduct a probabilistic sensitivity analysis because we do not have grounds for putting a probability distribution on the important sources of uncertainty to be evaluated. Our 3-way deterministic sensitivity analysis found that our results were robust.
Although Dr. Cressman and colleagues make several important points, it is unclear how they relate to our main finding: the gradient of the cost-effectiveness of screening in high-versus low-risk patients. This factor is the main determinant of the net benefit of risk targeting compared with a broader screening selection strategy, such as following NLST or U.S. Preventive Services Task Force criteria. Other alternative stratifications may prove more cost-effective than either broad criteria or a risk-targeted strategy. These approaches would need to better account for not only the risk for lung cancer mortality but also the competing risk for death from other causes to select patients likely to gain the most qualityadjusted life-years by, for example, risk targeting after deselecting patients with a relatively limited life expectancy (3). 
TO THE EDITOR:
We are concerned that various aspects of Kunisaki and colleagues' systematic review (1) severely limit their conclusions. The authors concluded that health care delivery to patients with obstructive sleep apnea by sleep specialist physicians (SSPs) was the same as that by non-sleep specialists (NSSs). Pooled analysis was not provided for adherence to continuous positive airway pressure therapy, 1 of the most important outcomes that influence the downstream health benefits of treating obstructive sleep apnea. Performing a meta-analysis of the same studies included by the authors revealed a mean difference of 29 minutes (95% CI, Ϫ5 to 63 minutes; P = 0.091) of nightly use of this therapy favoring SSPs with consistency (I 2 = 0%; P = 0.44). If we include our previous study (n = 502) (2) to their meta-analysis, we find greater adherence to continuous positive airway pressure therapy by 40 minutes (CI, 10 to 70 minutes; P = 0.008) in the SSP group with consistency (I 2 = 10%; P = 0.35). Our study involved prospectively enrolled participants in a multicenter, real-world setting but was excluded for unclear reasons. Included studies also were misclassified in that studies with groups that included nurses with 15 years of experience in managing sleep patients or who were trained in sleep medicine were categorized as NSSs. Other studies focused more on how they were scored rather than how health care was delivered. Most included studies did not consider the accreditation status of the sleep center and by ignoring the context and setting did not account for the effect of care delivery protocols and attendant quality metrics. Moreover, most included studies were not performed in the United States, thus limiting the generalizability of this study within that country.
The authors suggest that large, pragmatic studies that include both nonacademic and academic settings are needed. Such studies are available but also were excluded for unclear reasons (2, 3) . In general, systematic reviews need to provide strict inclusion and exclusion criteria that are devoid of bias even though the authors may exercise a consensusderived decision to exclude certain "inconvenient" data. Guidelines from PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) require that reasons for exclusion of individual studies, measures of consistency of the pooled analysis, and sensitivity analyses are provided. Other guidelines recommend that investigators contact authors of published data for additional information if needed (4 IN RESPONSE: Dr. Parthasarathy and colleagues suggest that several aspects of our systematic review limit our conclusions. We disagree.
First, we noted the limitations in, and low strength of, the evidence indicating that care by NSSs and SSPs resulted in similar outcomes in adults with known or suspected obstructive sleep apnea.
Second, we did not provide pooled results, because of the paucity and heterogeneity of studies reporting quality of life, adherence, and Epworth Sleepiness Scale (ESS) scores, a decision suggested by the journal's editors. We noted that none of the 5 randomized controlled trials reporting adherence found a statistically or clinically significant difference between the NSS and SSP groups. The pooled adherence results provided by Dr. Parthasarathy and colleagues were not statistically significant, and their reported mean difference did not achieve the "clinically important threshold" defined by a consensus of selected sleep experts and adopted by the American Academy of Sleep Medicine (1). We also described that care provided by both NSSs and SSPs resulted in clinically significant mean reductions in daytime sleepiness from baseline as measured by ESS scores but that there were no between-group differences when comparing NSS with SSP care. Care provided by both NSSs and SSPs resulted in clinically significant mean reductions in daytime sleepiness from baseline as defined by a consensus-based, 2-point improvement in the ESS score. There were no between-group differences in ESS score improvement when comparing NSS with SSP care. Third, our explicitly stated focus was the comparison of outcomes associated with care provided by SSPs versus that offered by providers with different qualifications. Nurses were therefore classified as NSSs even if they were highly experienced in sleep medicine. We noted the high level of experience of NSSs in these studies, raised caution about widespread implementation, and encouraged research in settings with less experienced NSSs. We excluded from our analysis the 2 studies referenced by Dr. Parthasarathy and colleagues (2, 3) because they compared board-certified SSPs or accredited facilities with non-board-certified SSPs or nonaccredited facilities rather than NSSs with SSPs. We cited these studies and their results in the Discussion section.
Finally, we strongly disagree with Dr. Parthasarathy and colleagues' suggestion that our review was biased and excluded "inconvenient" data. We adhered to the PRISMA checklist (4) and used standard methods for literature searching, study selection, data synthesis, and assessment of risk of bias and strength of evidence. Our review underwent extensive peer review and revisions.
In summary, given the limited supply of SSPs and the high prevalence of obstructive sleep apnea, our systematic review indicates that some initial diagnosis and management of suspected obstructive sleep apnea might be feasible by NSSs with subspecialty support for more complex cases. However, further studies are needed to determine whether NSSs can achieve similar outcomes to SSPs in nonacademic centers and among primary care providers without extensive sleep medicine experience.
IN RESPONSE: Dr. Robbins suggests that using estrogen without a progestogen but with regular endometrial surveillance is a reasonable approach to hormone therapy, especially given the results of the WHI trial showing that breast cancer risk was slightly reduced in the unopposed estrogen group compared with the placebo group (for breast cancer mortality, the hazard ratios were 1.44 [95% CI, 0.97 to 2.15; P = 0.07] for conjugated equine estrogen plus MPA and 0.55 [CI, 0.33 to 0.92; P = 0.02] for conjugated equine estrogen alone) (1). Although this difference may suggest an adverse effect of progestogens on breast tissue, the reason for this comparative reduction in cancer risk in the unopposed estrogen group is not well understood. The guideline says, "The primary menopause-related indication for progestogen use is to prevent endometrial overgrowth and the increased risk of endometrial cancer during [estrogen therapy] use" (2) . Avoiding endometrial cancer and hyperplasia seems justified.
The recommendation for a combination hormonal approach is standard in the United States. However, regimens and progestogens vary and data are lacking to advise the best method, including formulation, dose, and manner of progestogen administration. As Richardson says in our article, little is known about the risks of progestogens. Some studies do suggest that micronized progesterone is safer than synthetic MPA (3). Although using a progestin-releasing intrauterine device for direct endometrial protection with systemic estrogen may seem appealing (and many women are treated this way), trials of this approach are lacking and recent data from Denmark suggest that long-term use of hormonal intrauterine devices for contraceptive purposes may slightly increase breast cancer risk (4) .
For individual women who have difficulty tolerating progestogens, we have each prescribed unopposed estrogen with surveillance. However, in our experience, adherence to a schedule of annual vaginal ultrasonography or endometrial biopsy is often difficult for patients and expensive for both them and the health care system. Furthermore, we are not aware of any studies of this approach. Because U.S. guidelines universally recommend protection with progestogens, it is difficult to be at ease using unopposed estrogen knowing that this approach will result in medical interventions and cases of endometrial cancer.
Politics and Professionalism
TO THE EDITOR: I appreciate Sexauer's insights (1) and wish to expand on 2 of his many valid points. Professionalism cannot be taught online. Vague lists of generally accepted virtuous actions are of little use in understanding the nature and purpose of professionalism or in reliably guiding behavior. Before the term "professional" was co-opted to describe play-ing golf for money, it meant publicly professing a commitment to one's vocation. This transformative oath explicitly changes one's very identity and defines a new, special relationship to those the vocation serves. It is the culmination of one's calling. By this oath, one submits to the authority of the institution into which one is entering, willingly assumes new responsibilities and constraints, and is granted new boundaries and authorities. I am a professed spouse, professed Christian, and professed physician. Many others also make public professions, including lawyers, clergy, the nation's military personnel, and public servants. Yes, politicians are professionals, too. As such, when they take their oaths of office, their identities, responsibilities, and authorities all change and they enter a new relationship with the persons and institutions they now serve. At least that's how it's supposed to work.
The foundation of any viable relationship-especially one of professional service-must be respect. In a democracy, where each citizen has equal voice and equal vote, citizens should also expect equal respect and civility from their public servants. Furthermore, in their oaths of office, public servants swear to respect the Constitution (and, by extension, the rule of law) on which our democracy was founded. However, our politicians seem to tolerate and even encourage disrespect of, well, everything-other people, boundaries, law, and even objective reality-and feel justified in doing so. Such "justified disrespect" is so foreign to physicians' concept of professionalism that it generates the severe dissonance so well reflected in Sexauer's essay.
Disrespect has been simmering in our nation for decades, but it now seems to be coming to a head. As such, issues of guns, the Black Lives Matter and #MeToo movements, white supremacy, gender identity, and many other conversations we never seemed to have no longer seem avoidable. Perhaps our democracy is nearing the point where, with civility and commitment to an objective reality, we will finally face and address these issues professionally. IN RESPONSE: I agree with Dr. Berger that the many and varied aspects of physician conduct encompassed under the term "professionalism" would be difficult to teach or enforce online. The skepticism communicated in my essay's first paragraph continues to this day. I also agree that one takes on a new set of responsibilities and a unique position of authority when one enters the medical field. However, I do not believe that the transition "changes one's very identity." I suspect that the set of qualities that underlie medical professionalism are present early-albeit perhaps underdeveloped-in optimal physician candidates. The challenge is to identify those candidates at the time of acceptance to medical schools and training programs and then grow and nurture those qualities throughout their training. The profession does not always get it right. I also contend that professing a commitment does not necessarily make one a professional, at least in the sense that this term is used in medicine. Taking the Hippocratic Oath does not ensure professionalism, but adhering to the tenets of that oath throughout a career goes a long way toward achieving the desired goal.
William Berger, MD
Not all politicians act unprofessionally or disrespectfully; in fact, most probably do not. However, too many in today's political landscape do, and these persons tend to garner the most attention. Recent attempts to have the difficult conversations that Dr. Berger alludes to are characterized more by the sides talking past each other rather than respectfully to each other. This does not bode well for the optimistic outlook expressed in his closing sentence. 
